Authors

Latest:

Expert Perspectives on Balancing Therapy Decisions and Quality of Life in mCRC

Panelists discuss how immunotherapy generally provides better quality of life compared to traditional chemotherapy, particularly noting that microsatellite instability-high patients on immune checkpoint inhibitors report significantly better experiences than those on FOLFOX regimens.

Maher Albitar, MD

Latest:

Inside the Clinic: Experts Explore Case Studies in DLBCL

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Faiz Bhora, MD, FACS

Faiz Bhora, MD, FACS, serves as Professor of Surgery at the Hackensack Meridian School of Medicine and holds the prestigious roles of Regional Chair of Surgery and Chief of Thoracic Surgery for Hackensack Meridian Health’s Central Region.

Latest:

Dr Bhora on How Perioperative Immunotherapy Is Reshaping the Treatment Paradigm in Resectable NSCLC

Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.

Russ Conroy

Latest:

Ziftomenib Plus Venetoclax and Azacitidine Is Tolerable and Active in NPM1/KMT2A+ AML

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

Suneel Kamath, MD

Latest:

Dr Kamath on the Rise in Incidence of Pancreatic Cancer

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Nader Sanai, MD

Latest:

Dr Sanai on the Evaluation of BDTX-1535 in EGFR-Mutated High-Grade Glioblastoma

Nader Sanai, MD, discusses a phase 1 trial investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma.

Florida Cancer Specialists & Research Institute

Latest:

Breaking New Ground in Biological Therapies for Cancer

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.

Tetiana Skrypets, MD, PhD

Tetiana Skrypets, MD, PhD, a clinical research physician in hematology in the Hematology and Cell Therapy Unit at the Istituto Tumori “Giovanni Paolo II”

Latest:

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Latest:

Investigational Agents for the Treatment of Advanced cSCC

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

Caspian Oliai, MD, MS

Latest:

Unanswered Questions and the Future for Orca-T: What’s Next?

Panelists discuss how unanswered questions regarding long-term outcomes and potential late toxicities, along with the need for further evaluation in specific patient subgroups, highlight the importance of continued research to refine the use of Orca-T across diverse populations.

Shernan Holtan, MD

Latest:

Multidisciplinary Approaches to GVHD

Medical experts discuss multidisciplinary approaches to GVHD.

Suzanne B. Coopey, MD, FACS

Latest:

Dr Coopey on Institutional and Societal Initiatives to Support Women in Oncology

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

Ariana Pelosci

Latest:

Ziftomenib at RP2D Demonstrates High Response Rates for NPM1-Mutated AML

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Neil Morganstein, MD

Latest:

The Future of Molecular Testing in NSCLC

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Naomi Dempsey, MD

Latest:

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Ani Balmanoukian, MD, The Angeles Clinic and Research Institute

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Ecaterina Ileana Dumbrava, MD

Ecaterina Ileana Dumbrava, MD is anAssistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Latest:

Dr Dumbrava on Targeting TP53 Y220C Mutations in Solid Tumors With Rezatapopt

Ecaterina Dumbrava, MD, discusses early findings of rezatapopt in patients with solid tumors harboring TP53 Y220C mutations.

Christopher Cutie, M.D., Vice President, Disease Area Leader, Bladder Cancer, Janssen Research & Development, LLC.

Vice President Disease Area Leader, Bladder Cancer Janssen Research & Development, LLC.

Latest:

How Advancing the Science of Bladder Cancer Aims to Transform Patients’ Lives

Attaya Suvannasankha, MD

Latest:

Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R Myeloma

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Joshua Hurwitz

Latest:

Hurwitz on the Safety Profile of Simultaneous Integrated Boost Plus SBRT in Prostate Cancer

Joshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.